TELA Bio (NASDAQ:TELA) Director Joseph Capper Purchases 25,000 Shares of Stock

Key Points

• Director Joseph Capper bought 25,000 TELA Bio shares at $1.22 each, investing $30,500 and increasing his direct ownership by 16.15% to 179,827 shares.
• TELA Bio shares recently traded at $1.25, with a market capitalization of approximately $56.4 million. The stock remains volatile, ranging from $0.50 to $1.69 over the past year.
• The company reported a quarterly loss of $0.20 per share and revenue of $19.29 million, both below analyst expectations. Analysts hold a consensus “Hold” rating with an average price target of $2.20, while institutional investors own 94.35% of the stock.

TELA Bio, Inc. (NASDAQ:TELA - Get Free Report) Director Joseph Capper purchased 25,000 shares of TELA Bio stock in a transaction on Thursday, September 17th. The stock was acquired at an average cost of $1.22 per share, for a total transaction of $30,500.00. Following the acquisition, the director directly owned 179,827 shares of the company's stock, valued at approximately $219,388.94. This represents a 16.15% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

TELA Bio Price Performance

Shares of TELA stock traded down $0.04 during trading hours on Friday, hitting $1.25. The company's stock had a trading volume of 479,477 shares, compared to its average volume of 186,919. The business has a fifty day moving average of $0.79 and a 200-day moving average of $0.79. The stock has a market cap of $56.43 million, a price-to-earnings ratio of -1.62 and a beta of 1.36. TELA Bio, Inc. has a twelve month low of $0.50 and a twelve month high of $1.69. The company has a current ratio of 2.99, a quick ratio of 2.38 and a debt-to-equity ratio of 8.82.

TELA Bio (NASDAQ:TELA - Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.03). TELA Bio had a negative return on equity of 1,320.81% and a negative net margin of 51.53%.The company had revenue of $19.29 million for the quarter, compared to analyst estimates of $20.01 million. As a group, equities research analysts anticipate that TELA Bio, Inc. will post -0.76 EPS for the current year.

Institutional Investors Weigh In On TELA Bio

Hedge funds and other institutional investors have recently made changes to their positions in the business. UP Strategic Wealth Investment Advisors LLC purchased a new position in TELA Bio during the second quarter worth about $91,000. BlackRock Inc. acquired a new position in shares of TELA Bio during the 2nd quarter valued at about $281,000. WealthTrust Axiom LLC increased its stake in shares of TELA Bio by 39.1% during the 4th quarter. WealthTrust Axiom LLC now owns 322,588 shares of the company's stock valued at $381,000 after acquiring an additional 90,650 shares during the last quarter. Perkins Capital Management Inc. lifted its holdings in shares of TELA Bio by 1.5% during the 1st quarter. Perkins Capital Management Inc. now owns 1,418,328 shares of the company's stock worth $879,000 after acquiring an additional 20,910 shares during the period. Finally, Stonepine Capital Management LLC purchased a new position in shares of TELA Bio during the 2nd quarter worth about $1,996,820. Hedge funds and other institutional investors own 94.35% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a "sell (e+)" rating on shares of TELA Bio in a report on Friday, July 17th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, TELA Bio currently has a consensus rating of "Hold" and an average target price of $2.20.

TELA Bio Company Profile

TELA Bio, Inc is a medical technology company focused on developing and commercializing implantable products for soft-tissue reconstruction. Its products are designed to support the repair and reinforcement of damaged or weakened soft tissue, including tissue affected by hernias, abdominal wall defects and other reconstructive procedures.

The company's principal product platform is OviTex Reinforced Tissue Matrix, a family of biologic implants that combines extracellular matrix tissue with a polymer reinforcement structure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.